



## Buprenorphine and Office-Based Treatment of Opioid Dependence

*For Physicians in Publicly Funded Hospitals*

**Saturday,  
March 29, 2008**

**8:00 am-5:15 pm**  
*Registration Begins  
at 7:00 am*

**Location:**  
Cicatelli Associates Inc.  
505 Eighth Avenue  
20th floor  
New York, NY 10018

This training is presented by:  
The American Psychiatric Association,  
Cicatelli Associates Inc.,  
and the New York City Department of Health and Mental Hygiene

### Invitation

You are invited to attend a day-long training on the use of buprenorphine in treating opioid addiction. Doctors who complete this training will qualify for a waiver to prescribe buprenorphine.

**Dates:** Saturday, March 29, 2008

**Time:** **7 am - 8 am** Breakfast and mandatory sign-in  
**8 am - 5:15 pm** Program including lunch  
**5:15** Mandatory sign-out

**Location:** Cicatelli Associates Inc.  
505 Eighth Avenue (@ 35th St.)  
20th floor  
NY, NY 10018

**Directions:** Subway - A,C,E,1,2,3 trains to 34th Street

**Cost:** Free

8.0 AMA PRA Category I Credit(s)<sup>TM</sup> available

**Accreditation:** This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through Cicatelli Associates Incorporated (CAI). CAI is accredited by the ACCME to provide continuing medical education for physicians. CAI designates this educational activity for a maximum of 8.0 AMA PRA Category I Credit(s)<sup>TM</sup>. Physicians should only claim credit commensurate with the extent of their participation in the activity.

**Disclosure:** The "Faculty Disclosure Policy" of the ACCME requires that faculty participating in a CME activity disclose to the audience any relationship with a pharmaceutical or equipment company which might pose a potential, apparent, or real conflict of interest in regard to their contribution to the activity, and any discussions of unlabeled or investigational use of any commercial product or device not yet approved in the United States.

**Petros Levounis, MD, M.A.** is on the speaker's bureaus of Forest, Pfizer, Cephalon, Takeda, and AstraZeneca. Dr. Levounis will discuss off-label uses of commercial products. **Edwin A. Salsitz, MD** is on the speaker's bureau of Reckitt Benckiser. **Andrew Kolodny, MD** has no relationships to disclose. There are no commercial supporters of this activity.

### Training Objectives

This course will provide information to participants interested in learning about the treatment of opioid dependence and, in particular, physicians who wish to provide office-based prescriptions of the medication buprenorphine. After successfully completing the course, physicians will have fulfilled the necessary training requirement and will qualify for a waiver to prescribe buprenorphine in an office-based setting. After participating in this course, participants should be able to describe:

- General aspects of opioid pharmacology
- Pharmacological characteristics of buprenorphine and its use for opioid dependence treatment
- Different levels of treatment services
- Psychiatric and medical co-morbidity
- Confidentiality

Finally, the course will utilize case-based, small-group discussions to illustrate and elaborate upon points brought up in didactic presentations.

For more information and to register, please call  
Miriam Grill at  
(212) 594-7741 ext. 215 or  
email mgrill@cicatelli.org



505 EIGHTH AVENUE,  
SIXTEENTH FLOOR  
NEW YORK, NY 10018



## Agenda

7:00 A.M.	Registration and sign-in, continental breakfast
8:00 A.M.	Overview of Opioid Dependence and DATA 2000
8:30 A.M.	General opioid Pharmacology & Pharmacology of Buprenorphine
9:00 A.M.	Patient Assessment & Selection
9:30 A.M.	Small Group/Case #1
10:15 A.M.	BREAK
10:30 A.M.	Efficacy and Safety of Buprenorphine
11:00 A.M.	Clinical Use: Induction, Stabilization, Maintenance, & Detoxification
11:30 A.M.	Confidentiality, Medical Records, Office Policies & Procedures
12:00 P.M.	Small Group/Case #2
12:45 P.M.	LUNCH/Self Study/Case #3
1:30 P.M.	Medical Co-Morbidity
2:00 P.M.	Psychiatric Co-Morbidity
2:30 P.M.	Small Group/Case #4
3:15 P.M.	BREAK
3:30 P.M.	Pain Patients and Other Special Populations
4:00 P.M.	Film: "A Medical Treatment for a Medical Condition"
4:30 P.M.	Q&A; Notification Form; Program Evaluation

## Buprenorphine Waiver Information

This program is part of a national training initiative which has been endorsed by the Federal Center for Substance Abuse Treatment (CSAT) and is sponsored by the American Psychiatric Association. Physicians who complete this course will be eligible to request a waiver to practice medication-assisted addiction therapy with buprenorphine for the treatment of opioid dependence.

The course satisfies the Drug Addiction Treatment Act (DATA) 2000 physician training requirement. It will provide information and training to participants interested in learning about the treatment of opioid dependence and, in particular, to physicians who wish to provide office-based treatment of opioid dependence with buprenorphine.

At the conclusion of the course, the physician participant will be eligible to ask the Secretary of Health and Human Services for a waiver of the special registration requirements defined in the Controlled Substances Act. When granted, the waiver permits the physician to prescribe buprenorphine in an office-based setting.

**In order for the APA to confirm your completion of the training, you must:**

- **Bring a photo identification to show as part of the sign-in process**
- **Have your medical license number with you**
- **Confirm your attendance with your signature at various times throughout the day**
- **Complete a form authorizing the APA to submit your name to the Department of Health and Human Services**

**Please note that the American Psychiatric Association cannot confirm training for those who arrive late or depart before the completion of the course.**

## Faculty

### **Petros Levounis, M.D., M.A.**

Director, The Addiction Institute of New York  
Chief, Division of Addiction Psychiatry,  
St. Luke's and Roosevelt Hospitals  
New York, NY

### **Edwin A. Salsitz, M.D.**

Medical Director, Office-Based Opioid  
Therapy,  
Dept. of Medicine, Beth Israel Medical Center  
New York, NY

### **Andrew Kolodny, M.D.**

Vice Chair, Department of Psychiatry  
Maimonides Medical Center  
Brooklyn, NY

## Registration

Name \_\_\_\_\_

Agency \_\_\_\_\_

Address \_\_\_\_\_

City, State, Zip \_\_\_\_\_

Daytime Tel. No. \_\_\_\_\_

Daytime Fax No. \_\_\_\_\_

Email \_\_\_\_\_

Specialty: \_\_\_\_\_

Medical License # \_\_\_\_\_

DEA # \_\_\_\_\_

Resident? Yes \_\_\_\_\_ No \_\_\_\_\_

**This training is supported by the New York City Department of Health and Mental Hygiene with funds from the New York City Council.**

For more information and to register, please call  
Miriam Grill at (212) 594-7741 ext. 215  
or email to [mgrill@cicatelli.org](mailto:mgrill@cicatelli.org)

Mail/fax completed form to:

**Cicatelli Associates Inc.**

505 Eighth Ave, 16th Floor  
New York, NY 10018

Attn: Miriam Grill

Fax: (212) 629-3321